Dr. Choueiri on the Biology of the CABOSUN Trial for RCC
Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the findings of the CABOSUN trial for patients with metastatic renal cell carcinoma (mRCC).
Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the findings of the CABOSUN trial for patients with metastatic renal cell carcinoma (mRCC).
The CABOSUN trial investigated cabozantinib (Cabometyx) versus sunitinib (Sutent) in patients with mRCC.
According to Choueiri, it is interesting to see that something that makes sense biologically was able translate to clinical outcomes. Cabozantinib appeared to be superior to sunitinib, which is what was seen in the results of the study, explains Choueiri.
